Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | General Counsel and Corp Secy | March 31, 2023 | April 04, 2023 |
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | COO, GENERAL COUNSEL &CORP SEC | July 30, 2021 | July 31, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date March 31, 2023 · Filed April 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-03-31 | Direct | 77,300 |
Reported balance
After 2023-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-31 · Grant · Acquired 77,300 · Balance 77,300 F1: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to the options vest in equal quarterly installments over two years beginning on January 1, 2023 with the first quarterly installment vesting on April 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to the options vest in equal quarterly installments over two years beginning on January 1, 2023 with the first quarterly installment vesting on April 1, 2023.
Eloxx Pharmaceuticals, Inc.
Report date July 30, 2021 · Filed July 31, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,699 |
Ending reported balance
After 2021-07-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-07-30 · Exercise / conversion · Acquired 1,563 · Balance 33,158 F1: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Row 2 · 2021-07-30 · Tax withholding · Disposed 459 · Balance 32,699 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,375 |
Reported balance
After 2021-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-30 · Exercise / conversion · Disposed 1,563 · Balance 9,375 F1: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
F4: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2023 Filed Apr 4, 2023 16:38 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 77,300 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001209191-23-022749 · doc4.xml · derivative · entry 1 Belloff Neil S. · CIK 0001741670 · General Counsel and Corp Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,300 Underlying: Common Stock · 77,300 shares Expires 2033-03-31 F1 · derivative.exercise_date: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to the options vest in equal quarterly installments over two years beginning on January 1, 2023 with the first quarterly installment vesting on April 1, 2023. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 19:03 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001209191-21-063723 · doc4.xml · derivative · entry 1 Belloff Neil S. · CIK 0001741670 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-11-08 F1 · derivative.exercise_date: Options issued under the issuer's 2016 Inducement Plan. Twenty-five percent of the shares subject to the options vest on November 8, 2022. The balance of the shares vest in equal quarterly installments over the three years thereafter. Read SEC document |
| July 30, 2021 Filed Jul 31, 2021 00:32 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003750 · form4-07302021_050735.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction. Read SEC document |
| July 30, 2021 Filed Jul 31, 2021 00:32 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 459 | $1.32 | $605.88 |
DisclosureSEC source: 0001415889-21-003750 · form4-07302021_050735.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,699 Read SEC document |
| July 30, 2021 Filed Jul 31, 2021 00:32 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003750 · form4-07302021_050735.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002682 · form4-05262021_040501.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through February 25, 2024, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 1,835 | $1.39 | $2,550.65 |
DisclosureSEC source: 0001415889-21-002682 · form4-05262021_040501.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,595 Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002682 · form4-05262021_040501.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| April 30, 2021 Filed May 3, 2021 14:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002227 · form4-05032021_100502.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,938 Underlying: Common Stock · 1,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction. Read SEC document |
| April 30, 2021 Filed May 3, 2021 14:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 459 | $2.18 | $1,000.62 |
DisclosureSEC source: 0001415889-21-002227 · form4-05032021_100502.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,180 Read SEC document |
| April 30, 2021 Filed May 3, 2021 14:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002227 · form4-05032021_100502.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| February 25, 2021 Filed Feb 27, 2021 00:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001001 · form4-02262021_070206.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through February 25, 2024, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| February 25, 2021 Filed Feb 27, 2021 00:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 7,338 | $3.95 | $28,985.10 |
DisclosureSEC source: 0001415889-21-001001 · form4-02262021_070206.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,077 Read SEC document |
| February 25, 2021 Filed Feb 27, 2021 00:05 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001001 · form4-02262021_070206.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:40 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 120,000 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000735 · form4-02172021_030226.xml · derivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-02-12 F1 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 12, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000501 · form4-02022021_040201.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 542 | $3.44 | $1,864.48 |
DisclosureSEC source: 0001415889-21-000501 · form4-02022021_040201.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,415 Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000501 · form4-02022021_040201.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002520 · form4-11022020_041102.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,063 Underlying: Common Stock · 1,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 459 | $2.53 | $1,161.27 |
DisclosureSEC source: 0001415889-20-002520 · form4-11022020_041102.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,394 Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002520 · form4-11022020_041102.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001981 · form4-07312020_040707.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 459 | $2.84 | $1,303.56 |
DisclosureSEC source: 0001415889-20-001981 · form4-07312020_040707.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,291 Read SEC document |
| July 30, 2020 Filed Jul 31, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001981 · form4-07312020_040707.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001104 · form4-05012020_050501.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,188 Underlying: Common Stock · 1,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 459 | $2.92 | $1,340.28 |
DisclosureSEC source: 0001415889-20-001104 · form4-05012020_050501.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,187 Read SEC document |
| April 30, 2020 Filed May 1, 2020 21:20 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-001104 · form4-05012020_050501.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:01 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-20-000500 · form4-02262020_040210.xml · derivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. F4 · derivative.expiration_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 00:01 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 200,000 | Not disclosed Strike: $3.59 | Not disclosed |
DisclosureSEC source: 0001415889-20-000500 · form4-02262020_040210.xml · derivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-02-25 F2 · price: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 25, 2021, and the remainder vesting in twelve equal quarterly installments thereafter. F1 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on February 25, 2021, and the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000195 · form4-01312020_050102.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · GENERAL COUNSEL/CORPORATE SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 2,166 | $3.91 | $8,469.06 |
DisclosureSEC source: 0001415889-20-000195 · form4-01312020_050102.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · GENERAL COUNSEL/CORPORATE SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,084 Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 22:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000195 · form4-01312020_050102.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · GENERAL COUNSEL/CORPORATE SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000639 · form4a-03042020_020316.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · shares: The original Form 4 filed on January 31, 2020 is amended by this Form 4 Amendment to correctly identify the nature of the transaction of the reporting person. F4 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F1 · derivative.expiration_date: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. F5 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 2,166 | $3.91 | $8,469.06 |
DisclosureSEC source: 0001415889-20-000639 · form4a-03042020_020316.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,084 Read SEC document |
| January 30, 2020 Filed Mar 4, 2020 19:30 UTC Amendment | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000639 · form4a-03042020_020316.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock. The original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0001415889-19-001017 · form4-09132019_040906.xml · derivative · entry 1 Belloff Neil S. · CIK 0001741670 · GENERAL COUNSEL/CORPORATE SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-09-12 F2 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on September 12, 2020, and the remainder vests in twelve equal quarterly installments thereafter. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 00:54 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000113 · form4-01312019_040128.xml · derivative · entry 2 Belloff Neil S. · CIK 0001741670 · GENERAL COUNSEL/CORPORATE SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. F4 · derivative.expiration_date: The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 00:54 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $11.53 | $0.00 |
DisclosureSEC source: 0001415889-19-000113 · form4-01312019_040128.xml · derivative · entry 1 Belloff Neil S. · CIK 0001741670 · GENERAL COUNSEL/CORPORATE SECR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-30 F2 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 21:34 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $20.85 | $0.00 |
DisclosureSEC source: 0001209191-18-038827 · doc4.xml · derivative · entry 1 Belloff Neil S. · CIK 0001741670 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-06-18 F1 · derivative.exercise_date: One third (1/3) of the shares underlying the option shall vest on June 18, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each quarterly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.